Published in Medical Letter on the CDC and FDA, October 15th, 2006
The contract will support research using Invitrogen's proprietary ProtoArray protein microarray technology to detect and analyze biothreat agents such as hemorrhagic fever viruses, poxviruses, and Bacillus anthracis (anthrax). This research will build upon work conducted under the original technical assistance agreement for $970,000 awarded in January 2006, which focused on the detection and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA